---
aliases: DMARD, Disease-modifying Antirheumatic drug
---
## Therapies: 
### DMARD: 
- **Conventional synthetic DMARDs (csDMARDs)**
	- [[Azathioprine]]
	- [[Cyclophosphamide  (CYC)]]
	- [[Mycophenolate mofetil (MMF)]]
	- [[Sulfasalazine]]
- **biologic DMARDs (bDMARDs)**
	- T-cell–modulating biologic 
		- [[Abatacept]]
	- B-cell cytotoxic agent 
		- [[Rituximab (RTX)]]
	- Anti–IL-6 receptor antibody 
		- [[Tocilizumab]]
		- [[Sarilumab]]
	- IL-1–inhibiting agents 
		- [[Anakinra]]
		- [[Canakinumab]]
		- [[Rilonacept]]
	- TNF-α–blocking agents 
		- [[Adalimumab]]
		- [[Certolizumab]]
		- [[Etanercept]]
		- [[Golimumab]]
		- [[Infliximab]]
- **targeted synthetic DMARD (tsDMARD)**
	- [[Tofacitinib]]
	- [[Baricitinib]]
- **窩不知道**
	- [[Apremilast]]
	- [[Belimumab]]
	- [[Ixekizumab]]
	- [[Secukinumab]]
	- [[Ustekinumab]]
### Small molecule drugs: 
- [[Azathioprine]]
- [[Cyclosporine and Tacrolimus]] $\rightarrow$ Calcineurin inhibitors
- [[Chloroquine and Hydroxychloroquine]]
- [[Cyclophosphamide  (CYC)]]
- [[Leflunomide]]
- [[Methotrexate (MTX)]]
- [[Mycophenolate mofetil (MMF)]]
- [[Sulfasalazine]]
### Gold salts: 
- no longer recommended (significant toxicities & questionable efficacy). 
## Combination therapy with DMARDs
The 2015 ACR guidelines for the treatment of rheumatoid arthritis: 
- combination of traditional DMARDs (eg, methotrexate, hydroxychloroquine, azathioprine) or addition of TNF inhibitors, non-TNF biologics, or small molecules. 
	- methotrexate + cyclosporine/ chloroquine/ hydroxychloroquine/ leflunomide/ infliximab/ adalimumab/ rituximab/ etanercept. 
	- Triple therapy: 
		- methotrexate, sulfasalazine, and hydroxychloroquine